lutadenovec autogene

AXP000161.1 · Cancer vaccine

Platform
chimpanzee adenovirus (ChAdV68, non-replicating)
Originator
Gritstone bio
Sponsor
Gritstone bio

Names

NameTypeSource
lutadenovec autogenepreferred name, INNcurator, ncit
GRT-C901codencit
Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901 ambiguoussynonymncit

Virus

Role
Vaccine vector
Family
Adenoviridae
Virus
chimpanzee adenovirus C68
Strain
ChAdV68
Replication
non replicating
Modifications
non-replicating great-ape adenovirus vector encoding a patient-specific cassette of up to 20 tumour-specific neoantigens
Transgenes
individualised tumour-specific neoantigens
Route
intramuscular
Source
evidence

Cross-references

NCI Thesaurus
C156925
FDA UNII
AJ42U9BVW4

Approvals

No regulatory approval recorded.

Clinical trials (3)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05456165Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon CancerWithdrawnPhase 22022-05-192022-09-010Colonic Neoplasms; Colorectal Neoplasms
NCT05141721A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal CancerActive not recruitingPhase 2/32022-02-122027-03700Colorectal Neoplasms
NCT03639714A Study of a Personalized Neoantigen Cancer VaccineCompletedPhase 1/22019-02-132022-11-1029Colorectal Cancer; Gastroesophageal Adenocarcinoma; Non Small Cell Lung Cancer; Urothelial Carcinoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 35970920Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.Nature medicine2022cited by trial NCT03639714

Notes

GRT-C901: individualised neoantigen priming vaccine on a chimpanzee adenovirus vector, the adenoviral half of the GRANITE regimen (prime GRT-C901, boost the self-amplifying mRNA GRT-R902 / sapecmeran autogene, NCIt C156926, which is a separate non-viral program outside this pass). Phase 2/3 in metastatic colorectal cancer; Gritstone filed for bankruptcy protection in 2024. Vector usually described as ChAdV68, derived from chimpanzee adenovirus C68; serotype not verified from a primary source here.

How to cite

lutadenovec autogene (AXP000161.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000161.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.